FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377014407> ?p ?o ?g. }

• W4377014407 endingPage "1123" @default.
• W4377014407 startingPage "1115" @default.
• W4377014407 abstract "OBJECTIVE: To assess cabergoline's efficacy at decreasing breast symptoms after second-trimester abortion or pregnancy loss. METHODS: This was a double-blinded, block-randomized superiority trial comparing cabergoline 1 mg once to placebo for preventing bothersome breast engorgement after second-trimester uterine evacuation. We enrolled pregnant people at 18–28 weeks of gestation who were English- or Spanish-speaking and without contraindication to the study drug. Participants completed a validated, piloted, electronic survey at baseline and at multiple timepoints through 2 weeks postprocedure to assess breast symptoms, side effects, and bother. Our primary outcome was any breast symptoms (a composite of engorgement, milk leakage, tenderness, and need for pain relief) on day 4; we planned to enroll 80 patients to show a 30% difference in breast symptoms (80% power, α=0.049). A subgroup of participants returned for serum prolactin levels. RESULTS: After screening 150 patients from April 2021 to June 2022, we enrolled 73 participants. Baseline demographics were balanced between groups: median gestational age was 21 weeks (range 18–26 weeks), 56.2% of participants were nulliparous, 34.2% self-identified as Hispanic, and 37.0% had public insurance. At baseline, reported breast symptoms were similar between groups. Among 69 participants who returned surveys on day 4, significantly fewer participants receiving cabergoline reported any breast symptoms compared with placebo (27.8% vs 97.0%, P <.001) (primary outcome) and fewer reported significant bother (2.8% vs 33.3%, P =.001) (secondary outcome). These differences persisted through day 14. Reported incidence and severity of bother from side effects were similar between groups: most common were constipation, fatigue, and headache. Serum prolactin levels were similar at baseline. On day 4, mean serum prolactin level was 6.5 ng/mL (SD 2.2) for those who received cabergoline and 18.0 ng/mL (SD 5.9) for placebo ( P =.049). CONCLUSION: Cabergoline is an effective and well-tolerated strategy to prevent breast symptoms after second-trimester abortion or pregnancy loss. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT04701333." @default.
• W4377014407 created "2023-05-19" @default.
• W4377014407 creator A5023011798 @default.
• W4377014407 creator A5027524396 @default.
• W4377014407 creator A5036357106 @default.
• W4377014407 creator A5056110386 @default.
• W4377014407 creator A5065933684 @default.
• W4377014407 creator A5070986543 @default.
• W4377014407 date "2023-05-03" @default.
• W4377014407 modified "2023-09-28" @default.
• W4377014407 title "Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss" @default.
• W4377014407 cites W1756840512 @default.
• W4377014407 cites W1976854631 @default.
• W4377014407 cites W1983586830 @default.
• W4377014407 cites W2001937433 @default.
• W4377014407 cites W2064801684 @default.
• W4377014407 cites W2069903347 @default.
• W4377014407 cites W2093274439 @default.
• W4377014407 cites W2113103296 @default.
• W4377014407 cites W2119989380 @default.
• W4377014407 cites W2127841934 @default.
• W4377014407 cites W2143180795 @default.
• W4377014407 cites W2253177242 @default.
• W4377014407 cites W2776436590 @default.
• W4377014407 cites W2954360884 @default.
• W4377014407 cites W3017974431 @default.
• W4377014407 cites W4236805817 @default.
• W4377014407 cites W4240633689 @default.
• W4377014407 doi "https://doi.org/10.1097/aog.0000000000005190" @default.
• W4377014407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37486652" @default.
• W4377014407 hasPublicationYear "2023" @default.
• W4377014407 type Work @default.
• W4377014407 citedByCount "1" @default.
• W4377014407 countsByYear W43770144072023 @default.
• W4377014407 crossrefType "journal-article" @default.
• W4377014407 hasAuthorship W4377014407A5023011798 @default.
• W4377014407 hasAuthorship W4377014407A5027524396 @default.
• W4377014407 hasAuthorship W4377014407A5036357106 @default.
• W4377014407 hasAuthorship W4377014407A5056110386 @default.
• W4377014407 hasAuthorship W4377014407A5065933684 @default.
• W4377014407 hasAuthorship W4377014407A5070986543 @default.
• W4377014407 hasBestOaLocation W43770144071 @default.
• W4377014407 hasConcept C126322002 @default.
• W4377014407 hasConcept C131872663 @default.
• W4377014407 hasConcept C142724271 @default.
• W4377014407 hasConcept C204787440 @default.
• W4377014407 hasConcept C27081682 @default.
• W4377014407 hasConcept C2778376644 @default.
• W4377014407 hasConcept C2779064019 @default.
• W4377014407 hasConcept C2779234561 @default.
• W4377014407 hasConcept C2779832395 @default.
• W4377014407 hasConcept C29456083 @default.
• W4377014407 hasConcept C46973012 @default.
• W4377014407 hasConcept C54355233 @default.
• W4377014407 hasConcept C71315377 @default.
• W4377014407 hasConcept C71924100 @default.
• W4377014407 hasConcept C86803240 @default.
• W4377014407 hasConceptScore W4377014407C126322002 @default.
• W4377014407 hasConceptScore W4377014407C131872663 @default.
• W4377014407 hasConceptScore W4377014407C142724271 @default.
• W4377014407 hasConceptScore W4377014407C204787440 @default.
• W4377014407 hasConceptScore W4377014407C27081682 @default.
• W4377014407 hasConceptScore W4377014407C2778376644 @default.
• W4377014407 hasConceptScore W4377014407C2779064019 @default.
• W4377014407 hasConceptScore W4377014407C2779234561 @default.
• W4377014407 hasConceptScore W4377014407C2779832395 @default.
• W4377014407 hasConceptScore W4377014407C29456083 @default.
• W4377014407 hasConceptScore W4377014407C46973012 @default.
• W4377014407 hasConceptScore W4377014407C54355233 @default.
• W4377014407 hasConceptScore W4377014407C71315377 @default.
• W4377014407 hasConceptScore W4377014407C71924100 @default.
• W4377014407 hasConceptScore W4377014407C86803240 @default.
• W4377014407 hasIssue "6" @default.
• W4377014407 hasLocation W43770144071 @default.
• W4377014407 hasLocation W43770144072 @default.
• W4377014407 hasOpenAccess W4377014407 @default.
• W4377014407 hasPrimaryLocation W43770144071 @default.
• W4377014407 hasRelatedWork W2029237212 @default.
• W4377014407 hasRelatedWork W2210870611 @default.
• W4377014407 hasRelatedWork W2333891256 @default.
• W4377014407 hasRelatedWork W3048306897 @default.
• W4377014407 hasRelatedWork W3163987424 @default.
• W4377014407 hasRelatedWork W3181785047 @default.
• W4377014407 hasRelatedWork W3192793103 @default.
• W4377014407 hasRelatedWork W4281694272 @default.
• W4377014407 hasRelatedWork W4323362705 @default.
• W4377014407 hasRelatedWork W985205842 @default.
• W4377014407 hasVolume "141" @default.
• W4377014407 isParatext "false" @default.
• W4377014407 isRetracted "false" @default.
• W4377014407 workType "article" @default.